Board of Directors

Xiaodong Wang, Ph.D., co-founded Sironax in 2017. He is the founding Director of the National Institute of Biological Sciences (NIBS) in Beijing and has been its Director and Investigator since 2010. He also co-founded BeiGene Ltd. (now BeOne Medicines – Nasdaq: ONC), where he is a board member and serves as Chairman of the Scientific Advisory Board.

Previously, Dr. Wang was a Howard Hughes Medical Institute Investigator from 1997 to 2010 and George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas from 2001 to 2010.

Dr. Wang has received multiple awards for his scientific achievements, including the Eli Lilly Award in Biological Chemistry from the American Chemical Society, ASBMB-Merck Award from the American Society for Biochemistry and Molecular Biology, the Award in Molecular Biology and Richard Lounsbery Award, both from the U.S. National Academy of Sciences, Outstanding Achievement Award from the American Association of Cancer Research, and the Shaw Prize in Life Science and Medicine.

Dr. Wang received a B.Sc. in biology from Beijing Normal University and a Ph.D. in biochemistry from the University of Texas Southwestern Medical Center. He has been a member of the U.S. National Academy of Sciences since 2004 and a foreign associate of the Chinese Academy of Sciences since 2013.

Dr. Shefali Agarwal has nearly 20 years of biotechnology and pharmaceutical industry experience spanning drug development, clinical research, commercial strategy, and regulatory affairs. As a trained physician, she combines medical, business, and public health knowledge to lead and contribute to innovative projects across therapeutic areas including oncology, immunology, hematology, neurology, and cardiovascular diseases. Dr. Agarwal has expertise in all stages of drug development, from preclinical to post-marketing, with a deep understanding of medical and regulatory processes ranging from Investigational New Drug Applications to New Drug Applications.

Before joining Sironax, Dr. Agarwal was President, CEO, and Chair of the Board at Onxeo S.A. (now Valerio Therapeutics), a clinical-stage biotechnology company focused on developing drugs targeting DNA Damage Response (DDR). Prior to Onxeo, she was Chief Medical Officer at Epizyme, a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases. There, she led the global clinical development and regulatory strategy for tazemetostat. Before joining Epizyme, Dr. Agarwal was CMO at SQZ Biotech and held leadership roles at Curis and Tesaro. At Curis, she oversaw the Phase II study of its HDAC/PI3K dual inhibitor in diffuse large B-cell lymphoma (DLBCL) and the Phase I study of the oral checkpoint inhibitor in solid tumors. At Tesaro, she led the NDA and European Medicines Agency submission for ZEJULA in ovarian cancer. Dr. Agarwal also held positions of increasing responsibility at Covidien, AVEO, and Pfizer.

Dr. Agarwal has received numerous awards for her achievements and contributions in drug development. In addition to a medical degree from The Johns Hopkins University School of Medicine, she has an MIS in information systems from the University of Maryland and an MBBS from Bangalore University. Currently, she serves on the boards of Fate Therapeutics, Gritstone Bio, and ITBMed, and as a member of the Scientific Advisory Board Committee at Imvax.

Albert Huang, Ph.D., is a Managing Director at Yunfeng Capital and has more than a decade of healthcare industry experience in R&D, business operations, and investment. Since joining Yunfeng in 2015, he has been leading the healthcare team and is responsible for private equity venture capital investment, mergers and acquisitions, and cross-border buyout transactions. Prior to Yunfeng Capital, he was a strategy consultant and project leader at Boston Consulting Group.

Dr. Huang received a bachelor’s degree in biological sciences from Tsinghua University and Ph.D. in biopharmaceuticals from Yale University. He is also current Secretary General of Tsinghua Biomedicine Yangtze River Delta (Y.R. Delta) Alumni Association.

Ranjeev Krishana has worked at Baker Bros. Advisors LP since 2011 and currently serves as Head of International Investments. Prior to joining Baker Bros., he held commercial, strategy, and business development leadership roles for Pfizer’s pharmaceutical business across international regions and markets, including Asia, Eastern Europe, and Latin America. Mr. Krishana worked at Pfizer from 2003 to 2007 and from 2008 to 2011. From 2008 to 2010, he was based in Beijing, where he served as Senior Director and a member of the Pfizer China leadership team. Mr. Krishana began his career as a strategy consultant at Accenture.

Mr. Krishana has a B.A. in economics and political science from Brown University and an MPP (Masters of Public Policy) from Harvard University.

Chong Xu, Ph.D., is a Partner at F-Prime Capital, focusing on the biopharmaceutical and medical technology sectors. He also works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime, Dr. Xu has been involved with numerous company formations including as a founding investor of AlphaGen Theraputics, Pediatrix, Skyline Tx, K36 Tx, and RareStone Group. Dr. Xu has held, or holds board positions on, OnCusp Tx, Remunix, Shinobi Tx, Semma Tx, Adagene, and Innovent. Prior to joining F-Prime in 2015, he was a management consultant at McKinsey & Company, a hedge fund healthcare equity analyst at Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Dr. Xu received a B.S. in biology from Zhejiang University, China; MBA from Darden School of Business, University of Virginia; and Ph.D. in cell biology from the University of Virginia.

Jason Zhang joined Hillhouse Investment in 2016 and is an Assistant Portfolio Manager on the Healthcare team in New York. Prior to joining Hillhouse, he worked at various investment firms in Hong Kong and the United States, focusing on public equities. He began his career as a management consultant at McKinsey & Company, working in their Shanghai and London offices.

Mr. Zhang has an MBA from The Wharton School, University of Pennsylvania, and a B.A. from Fudan University.

Jingwen Miao joined Temasek in 2014 and is currently Managing Director, China, overseeing Temasek’s Life Sciences investment efforts in China.

Ms. Miao began her career at Morgan Stanley’s Investment Banking Division, focusing on providing financial advisory services to clients in the transportation and industrials sectors. She subsequently entered the private equity industry and joined the Carlyle Group’s Asia Buyout Fund, focusing on investment in sectors including healthcare, consumer, retails, and industrials.

Ms. Miao has a B.A. in business administration from Fudan University.

Jiangtao Yu, Ph.D., is a Managing Director of Gaorong Capital. His investment interest focuses on first-in-class therapeutics with large unmet medical needs and breakthrough biotechnology platforms. Companies under his management include Alto Neuroscience (NYSE: ANRO), Cascade Pharmaceuticals, MingMed Biotech, Allink Biotherapeutics, 4B Biotechnologies, and Hygea MedTech.

Prior to Gaorong Capital, Dr. Yu was Assistant President of the Yangtze Delta Region Institute of Tsinghua University, leading cross-border technology transfer and high-tech startup incubation. He started his career in the Digital Health Group of Intel Corporation and later worked in the New Business Initiatives of Intel Capital.

Dr. Yu has a B.S. and M.S. from Tsinghua University and a Ph.D. from Cornell University.

Hu Li, Ph.D., is a Venture Partner for Eight Roads in Shanghai, working with their venture capital teams and the F-Prime team to evaluate therapeutic investment and company-creation opportunities and manage portfolio companies. Companies under his management include Alternative Bio, AlphaGen Therapeutics, and Ray Medicine.

Dr. Li is an accomplished drug discovery and development professional with over 25 years of experience in biologics and small molecules in oncology and other therapeutic areas. Previously, he was a co-founder and Vice President of Shanghai Miracogen (acquired by Lepu Biopharma in 2020, listed in HKEX), was with GSK R&D in Philadelphia, and served as a Discovery Biology Consultant for Scinovo. He has a proven track record of leading discovery research and non-clinical development for antibody drug conjugate and small molecular programs.

Dr. Li has a B.Sc. in chemistry from Nanjing University, M.Sc. in bioinorganic chemistry from the Chinese Academy of Science & Technology, and Ph.D. in biochemistry from Bryn Mawr College.